Long Shenrong announced: Its holding subsidiary, Pu'an Pharmaceutical, has obtained the qualification for the listing and sales of Tongmai Oral Liquid.

Long Shenrong announced that its holding subsidiary, Gansu Pu'an Pharmaceutical Co., Ltd. recently obtained the "On-site Inspection and Initial Product Inspection Registration Documents before Drug Listing" approved and issued by the Gansu Provincial Food and Drug Administration, and the Tongmai Oral Liquid is officially qualified for sale. This product functions to promote blood circulation and open up the meridians, and is used for ischemic cardiovascular and cerebrovascular diseases, arteriosclerosis, cerebral thrombosis, cerebral ischemia, angina pectoris, and coronary heart disease. Due to various factors affecting drug production and sales, there is uncertainty, so investors are advised to make decisions cautiously and pay attention to investment risks.